• SPX
  • 5969.34
  • 0.35 %
  • 20.6299
  • DJI
  • 44296.51
  • 0.97 %
  • 426.1602
  • N225
  • 38283.85
  • 0.68 %
  • 257.6797
  • FTSE
  • 8262.08
  • 1.38 %
  • 112.8101
  • IXIC
  • 19003.65
  • 0.16 %
  • 31.2305
Molecular Partners AG (MOLN) Stock Price, News & Analysis

Molecular Partners AG (MOLN) Stock Price, News & Analysis

Currency in USD Disclaimer

$5.29

-$0.15

(-2.85%)

Day's range
$5.29
Day's range
$5.29
50-day range
$4.37
Day's range
$7.6
  • Country: CH
  • ISIN: US60853G1067
52 wk range
$3.32
Day's range
$12.7
  • CEO: Dr. Patrick Amstutz Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 6.07
  • Piotroski Score 2.00
  • Grade Neutral
  • Symbol (MOLN)
  • Company Molecular Partners AG
  • Price $5.29
  • Changes Percentage (-2.85%)
  • Change -$0.15
  • Day Low $5.29
  • Day High $5.29
  • Year High $12.70

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/06/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $29.00
  • High Stock Price Target $29.00
  • Low Stock Price Target $29.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.00
  • Trailing P/E Ratio -2.03
  • Forward P/E Ratio -2.03
  • P/E Growth -2.03
  • Net Income $-61,984,000

Income Statement

Quarterly

Annual

Latest News of MOLN

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Molecular Partners AG Frequently Asked Questions

  • What were the earnings of MOLN in the last quarter?

    In the last quarter Molecular Partners AG earnings were on Thursday, October, 31st. The Molecular Partners AG maker reported -$0.57 EPS for the quarter, beating analysts' consensus estimates of -$0.63 by $0.06.

  • What is the Molecular Partners AG stock price today?

    Today's price of Molecular Partners AG is $5.29 — it has decreased by -2.85% in the past 24 hours. Watch Molecular Partners AG stock price performance more closely on the chart.

  • Does Molecular Partners AG release reports?

    Yes, you can track Molecular Partners AG's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Molecular Partners AG stock forecast?

    Watch the Molecular Partners AG chart and read a more detailed Molecular Partners AG stock forecast to see what analysts suggest you do with its shares.

  • What is Molecular Partners AG stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Molecular Partners AG stock ticker.

  • How to buy Molecular Partners AG stocks?

    Like other stocks, MOLN shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Molecular Partners AG's EBITDA?

    Molecular Partners AG measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Molecular Partners AG’s financial statements.

  • What is the Molecular Partners AG's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -8.8070474567, which equates to approximately -880.70%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Molecular Partners AG stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Molecular Partners AG's financials relevant news, and technical analysis. Molecular Partners AG's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Molecular Partners AG stock currently indicates a “sell” signal. For more insights, review Molecular Partners AG’s technical analysis.

  • A revenue figure for Molecular Partners AG for its last quarter?

    Molecular Partners AG published it's last quarterly revenues at $681,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.